Zibotentan Clinical Trials (2026): 18 Studies for Liver Cirrhosis & Chronic Kidney Disease
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
18 Zibotentan clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 14 indications (including Liver Cirrhosis & Chronic Kidney Disease) and 3,613 total planned enrollment. 1 Phase 3 Zibotentan trial and 10 Phase 2 are listed. 1 Zibotentan clinical trial is actively recruiting. Most recent activity: NCT06087835 (Feb 2027).
Zibotentan clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | Total |
|---|---|---|---|---|---|
| P1 | 7 | 7 | |||
| P2 | 1 | 7 | 2 | 10 | |
| P3 | 1 | 1 |
Recruiting Zibotentan clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06942910 | ZODIACA Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria | P2 | Chronic Kidney Disease With High Proteinuria | 224 | May 2025 |
Zibotentan clinical trials by indication
Liver Cirrhosis (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05516498 | ZEAL | P2 | terminated | Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study) |
| NCT06715670 | — | P1 | completed | A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants |
| NCT06269484 | ZEAL UNLOCK | P2 | completed | A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK |
Chronic Kidney Disease With High Proteinuria (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06087835 | — | P3 | active not recruiting | Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) |
| NCT06942910 | ZODIAC | P2 | recruiting | A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria |
Chronic Kidney Disease (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04724837 | ZENITH-CKD | P2 | completed | Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial) |
| NCT04991571 | — | P1 | completed | Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants |
Healthy Participants (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07404137 | — | P1 | completed | A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food |
Chronic Kidney Diseases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05570305 | ZODIAC | P2 | completed | Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria |
Healthy Female Participants (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05505162 | — | P1 | completed | Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential. |
Hepatic Impairment (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05112419 | — | P1 | completed | A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment |
Microvascular Angina (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04097314 | PRIZE | P2 | completed | Precision Medicine With Zibotentan in Microvascular Angina |
Scleroderma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02047708 | ZEBRA | P2 | completed | Zibotentan Better Renal Scleroderma Outcome Study |
Peripheral Arterial Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01890135 | — | P2 | completed | Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent Claudication |
Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01205711 | FOLFERA | P2 | completed | Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer |
Advanced Solid Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00997945 | — | P1 | completed | 10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies |
Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00929162 | — | P2 | terminated | ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer |
Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00314782 | — | P1 | completed | Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC |
Zibotentan pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ZODIAC | NCT06942910 | P2 | recruiting | Chronic Kidney Disease With High Proteinuria | 224 | — |
| ZEAL | NCT05516498 | P2 | terminated | Liver Cirrhosis | 205 | — |
| ZODIAC | NCT05570305 | P2 | completed | Chronic Kidney Diseases | 42 | PMID 41805697 |
| ZEAL UNLOCK | NCT06269484 | P2 | completed | Liver Cirrhosis | 73 | — |
| PRIZE | NCT04097314 | P2 | completed | Microvascular Angina | 225 | PMID 41687797 |
| ZENITH-CKD | NCT04724837 | P2 | completed | Chronic Kidney Disease | 542 | PMID 33990507 |
| ZEBRA | NCT02047708 | P2 | completed | Scleroderma | 27 | PMID 35650639 |
| FOLFERA | NCT01205711 | P2 | completed | Colorectal Cancer | 111 | — |
Terminated and withdrawn Zibotentan trials (2)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05516498terminatedZibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
- NCT00929162terminatedZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer
All Zibotentan trials (18)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06087835 | Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) | P3 | active not recruiting | 1,835 | AstraZeneca | Nov 2023 | |
| NCT06942910 | ZODIAC | A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria | P2 | recruiting | 224 | AstraZeneca | May 2025 |
| NCT07404137 | A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food | P1 | completed | 26 | AstraZeneca | Feb 2026 | |
| NCT05516498 | ZEAL | Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study) | P2 | terminated | 205 | AstraZeneca | Oct 2022 |
| NCT05570305 | ZODIAC | Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria | P2 | completed | 42 | University Medical Center Groningen | Oct 2022 |
| NCT06715670 | A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants | P1 | completed | 30 | AstraZeneca | Dec 2024 | |
| NCT06269484 | ZEAL UNLOCK | A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK | P2 | completed | 73 | AstraZeneca | Feb 2024 |
| NCT04097314 | PRIZE | Precision Medicine With Zibotentan in Microvascular Angina | P2 | completed | 225 | NHS Greater Glasgow and Clyde | Oct 2019 |
| NCT04724837 | ZENITH-CKD | Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial) | P2 | completed | 542 | AstraZeneca | Apr 2021 |
| NCT05505162 | Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential. | P1 | completed | 24 | AstraZeneca | Aug 2022 | |
| NCT05112419 | A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment | P1 | completed | 12 | AstraZeneca | Nov 2021 | |
| NCT04991571 | Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants | P1 | completed | 27 | AstraZeneca | Jul 2021 | |
| NCT02047708 | ZEBRA | Zibotentan Better Renal Scleroderma Outcome Study | P2 | completed | 27 | University College, London | Oct 2014 |
| NCT01890135 | Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent Claudication | P2 | completed | 31 | University of Virginia | Jun 2013 | |
| NCT01205711 | FOLFERA | Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer | P2 | completed | 111 | Cardiff University | Apr 2010 |
| NCT00929162 | ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer | P2 | terminated | 120 | AstraZeneca | Jun 2009 | |
| NCT00997945 | 10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies | P1 | completed | 15 | AstraZeneca | Oct 2009 | |
| NCT00314782 | Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC | P1 | completed | 44 | AstraZeneca | Mar 2006 |
Zibotentan clinical trials: frequently asked questions
- How many Zibotentan clinical trials are there?
- 18 Zibotentan clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 14 are marked completed.
- Are Zibotentan clinical trials recruiting in 2026?
- Yes — 1 Zibotentan trial is actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is Zibotentan being studied for?
- Zibotentan is being studied for Liver Cirrhosis, Chronic Kidney Disease, Chronic Kidney Disease With High Proteinuria, Healthy Female Participants, Healthy Participants and 12 more. The trials are grouped by indication on this page.
- What phase is Zibotentan in?
- Zibotentan clinical trials span 1 Phase 3, 10 Phase 2, 7 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Zibotentan clinical trials?
- The lead sponsor across the most Zibotentan trials is AstraZeneca, with 5 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Zibotentanas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: